MAPK3 and neoplasm: Immunoblot analyses of tumor xenografts corroborated our in vitro findings and revealed decreased expression of phosphorylated ERK1/2, MEK1/2, and Stat3 in the combination treatment group compared to either monotherapy (Figure 4B).